FDA Grants Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for R/R Metastatic CRC May 21, 2024
Approvals received for BRAFTOVI and MEKTOVI for Expanded Use for Two New Indications in Japan May 21, 2024
